Findings of the systematic literature review on treatment options for enthesitis
| Disease | Tested drug vs Reference | Superiority of the treatment arm against reference arm (p<0.05) | Reference |
| PsA | TNFi vs PBO | YES | NCT00051623 (IFX) NCT00265096 (GOL) NCT01087788 (CZP) |
| TNFi+MTX vs PBO+MTX (PBO+ETN one study) vs PBO+MTX | NO | NCT00367237 (IFX) NCT02065713 (GOL) NCT02376790 (ETN) | |
| UST vs PBO | YES | NCT01009086 NCT01077362 | |
| UST vs TNFi | YES | EudraCT 2017-003799-29 β | |
| GUS q4w vs PBO GUS q8w vs PBO | YES NO | NCT03162796 NCT03158285 | |
| SEC (pooled dose) vs PBO | YES | NCT01392326 NCT01752634 | |
| SEC 300mg vs PBO SEC 150mg vs PBO | YES NO | NCT01989468 | |
| SEC 300mg with loading vs PBO SEC 150mg with loading vs PBO SEC 150mg no loading vs PBO | YES YES NO | NCT02404350 | |
| IXE vs PBO ADA vs PBO | YES NO PsA Bionaive | NCT01695239 | |
| IXE vs PBO | NO PsA Bioexperienced | NCT02349295 | |
| IL17i (SEC/ ADA) vs TNFi | NO | NCT02745080 (SEC) NCT03151551 (ADA) β | |
| APR 20mg vs PBO APR 30mg vs PBO | NO YES | NCT01172938 | |
| TOF 5mg vs PBO TOF 10mg vs PBO ADA 40mg vs PBO | NO YES NO | NCT01877668 (TNFi-naive) | |
| TOF vs PBO | NO | NCT01882439 (TNFi-failure) | |
| SpA | ETN vs SSZ | YES (imaging)/ NO (clinical) axSpA | NCT00844142 |
| ETN vs PBO | YES for nr-axSpA | NCT01258738 | |
| ADA vs PBO | YES for r-axSpA NO for nr-axSpA YES for perSpA | NCT00195819 NCT00939003 NCT01064856 | |
| GOL IV vs PBO | YES for r-axSpA | NCT02186873 | |
| GOL 100mg vs PBO GOL 50mg vs PBO | YES NO For r-axSpA | NCT00265083 | |
| GOL vs PBO | YES nr-axSpA | NCT01453725 |
β-Open-label; PsA: Psoriatic arthritis; r-axSpA: Radiologic axial spondylarthritis; nr-axialSpA: non radiological axial spondylarthritis; PBO: Placebo; TNFi: Tumor necrosis factor inhibitors; ETN: Etanercept; IFX: Infliximab; ADA: Adalimumab; GOL: Golimumab; UST: Ustekinumab; CZP: Certolizmab; GUS: Guselkumab; SEC: Secukinumab; IXE: Ixekizumab; APR: Apremilast; TOF: Tofacitinib; MTX - Methotrexate